Výsledky vyhledávání - "Laura Viggiano"

Abstract B23: microRNA attenuated oHSV-1 armed with multiple immunomodulatory payloads mediates robust and selective antitumor immune response in preclinical tumor models

Publikováno v: Cancer Immunology Research. 8:B23-B23

Although oncolytic viruses have shown clinical efficacy for local treatment of cancerous tumors, the ability to induce immune-mediated regression to visceral lesions is not robust. Immune checkpoint modulation has been efficacious in a fraction of ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e9b45fcb32c487c6e1a16aaa7a774ea4
https://doi.org/10.1158/2326-6074.tumimm18-b23

Zobrazit plný text záznamu

Abstract 4698: ONCR-1, a novel herpes simplex virus expressing MMP9 and ULBP3 transgenes, evokes potent oncolysis and development of antitumor immune responses

Autor: Weiguo Yao, Alexandra Hicks, Jacqueline Gursha, Michael Paglia, Lorenz Ponce, Jingzang Miu, Terry Farkaly, Joseph C. Glorioso, Daniel Wambua, Christophe Quéva, Michael Ball, Cecilia Kwong, Finer Mitchell H, Kyle Grant, Paola Grandi, Laura Viggiano Salta

Publikováno v: Cancer Research. 78:4698-4698

Glioblastoma multiforme (GBM) is a highly aggressive brain tumor associated with poor prognosis and resistance to current therapies. ONCR-1 is a novel oncolytic herpes simplex virus type-1 vector in development for the treatment of GBM. ONCR-1 utiliz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc51e0b4eb6496f98122ef71a7d21efa
https://doi.org/10.1158/1538-7445.am2018-4698

Zobrazit plný text záznamu

Characterization of Lentiviral Vector Derived Anti-Bcma CAR T Cells Reveals Key Parameters for Robust Manufacturing of Cell-Based Gene Therapies for Multiple Myeloma

Autor: Mark D. Angelino, Mingli Li, Laura Viggiano, Gregory Hopkins, Alden Ladd, Michael Kuczewski, Daniel Cossette, Richard A. Morgan, Graham Lilley, Wendy Bakeman, Michael J. Paglia, Kevin Friedman, John W. Evans, Dawn Maier, Kayla MacLeod, Sara M. Miller, Howard J. Latimer

Publikováno v: Blood. 126:3243-3243

T cells engineered with chimeric antigen receptors (CAR) specific to CD19 have caused rapid and durable clinical responses in ~90% of patients with acute lymphoblastic leukemia. These data support the development of additional CAR T cell products for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e389edec19dc7f9f2dc569053a39897
https://doi.org/10.1182/blood.v126.23.3243.3243

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání